Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 13,745 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: E Coli Infection
Interventions: no Intervention; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 300 participants
Timeline: 2020 – 2021
U.S. locations: 13
States / cities: Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, insulin detemir, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 60
States / cities: Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more

Conditions: Cannabis Use, Tobacco Use, Cigarette Smoking
Interventions: THC 30mg, THC 5mg, THC 0mg, Cigarette Full Nicotine, Cigarette Reduced Nicotine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions: silevertinib in combination with temozolomide, temozolomide (TMZ); Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 33 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK2256294, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma, Soft Tissue Sarcoma, Gastric/Esophageal Adenocarcinoma, Pancreatic Cancer Including Ampulla of Vater
Interventions: brivanib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 6
States / cities: Chicago, Illinois • Evanston, Illinois • Baltimore, Maryland + 2 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: ABT-263, FCR, BR; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: La Jolla, California • Stanford, California • Baltimore, Maryland + 3 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: afatinib, placebo; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 272
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Oral Cancer
Interventions: Mycoach Smart Text, MyCoach on Amazon Alexa; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions: Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 174
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more

Conditions: Medulloblastoma
Interventions: Lomustine, Vincristine, Cisplatin, Cyclophosphamide, Mesna; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 3 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 16
States / cities: Phoenix, Arizona • Aurora, Colorado • Orlando, Florida + 13 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Ibrutinib, Bendamustine hydrochloride, Rituximab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 39 more

Conditions: Macular Degeneration
Interventions: VEGF Trap Eye; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 33
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more

Conditions: Shigella
Interventions: ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU; Biological · Other
Lead sponsor: Eveliqure Biotechnologies GmbH; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Pancreatic Cancer
Interventions: Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Delayed Graft Function
Interventions: QPI-1002, Placebo; Drug · Other
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Kidney Cancer
Interventions: DHA-paclitaxel; Drug
Lead sponsor: Theradex; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 7
States / cities: Tucson, Arizona • Los Angeles, California • Lexington, Kentucky + 4 more

Conditions: Advanced Gastric Adenocarcinoma
Interventions: Paclitaxel, Olaparib, Pembrolizumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neoplasms, Brain
Interventions: Dabrafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 17 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 8
States / cities: Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more

Conditions: Bipolar Disorder
Interventions: Quetiapine Fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Cerritos, California + 33 more

Conditions: Tuberculosis
Interventions: Moxifloxacin, Isoniazid; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 3 more

Conditions: Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Interventions: Remestemcel-L, Placebo; Biological · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Los Angeles, California • Stanford, California + 16 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab Injection, Pembrolizumab Injection; Biological
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 97
States / cities: Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more

Conditions: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Nivolumab, Everolimus; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 39
States / cities: Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 29 more

Search by objective public record fields.

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Effect of Cannabis on Cigarette Use Behavior

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Physical Activities by Technology Help (PATH)

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression

TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment

MSCs in COVID-19 ARDS

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)